Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Perrigo: Receives FDA go-ahead to manufacture clemastine fumarate tablets 1.34 mg with the agency's approval of an ANDA, the company announced Dec. 5. Perrigo has been selling a store-brand version of Sandoz' Tavist-1 antihistamine with ingredient obtained from an outside supplier. Perrigo also sells a store-brand equivalent of Tavist-D with clemastine fumarate 1.34 mg and phenylpropanolamine hydrochloride 75 mg, extended release, under a licensing agreement with Sandoz ("The Tan Sheet" Sept. 19, 1994, p. 4)...

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel